Neumora Therapeutics, Inc. Common Stock
NMRANeumora Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for central nervous system (CNS) disorders. It leverages innovative neuroscience science and digital health tools to create precision medicines aimed at improving outcomes for patients with neurological and psychiatric conditions.
Company News
Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, highlighting its pipeline of novel neurological treatments, including a potential NLRP3 inhibitor for obesity and a vasopressin receptor antagonist for Alzheimer's disease agitation.
Neumora Therapeutics is initiating a Phase 1 clinical study for NMRA-861, a novel brain disease treatment with potential best-in-class pharmacology and no observed convulsions in pre-clinical studies.
Neumora Therapeutics initiated a Phase 1 clinical study of NMRA-861, a positive allosteric modulator targeting M4 muscarinic receptors for potential schizophrenia treatment. The study aims to evaluate safety, tolerability, and pharmacokinetics in healthy adults and those with stable schizophrenia.
Kuehn Law, a shareholder litigation law firm, is investigating whether certain officers and directors of Grocery Outlet Holding Corp. (GO) breached their fiduciary duties to shareholders. The firm is also investigating Neumora Therapeutics, Inc. (NMRA) and Solaris Energy Infrastructure, Inc. (SLRS).
